---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-25-000004"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2025-01-23T23:59:59+00:00"
generated_at: "2026-05-27T16:54:55.098568+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lisata reports Phase 2 ASCEND Cohort A: mOS 12.68 vs 9.72 months; 4 complete responses

## Summary
- Cohort A: median OS of 12.68 months for certepetide plus chemo vs 9.72 months for placebo plus chemo.
- Complete responses: 4 of 65 (6.2%) in certepetide group; 0 of 28 in placebo group.
- Median PFS was 5.5 months in both arms; 6-month PFS trend favored certepetide.
- Cohort B (two-dose regimen) data expected in coming months; full data from both cohorts to follow.
- Lisata plans to advance certepetide to Phase 3 in early 2026.

## SEC filing metadata
- accession: 0000320017-25-000004
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2025-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001725000004/0000320017-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001725000004/clbs-20250122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-25-000004
- JSON: https://secwatch.observer/filing/0000320017-25-000004.json
- Plain text: https://secwatch.observer/filing/0000320017-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.